AMGN Amgen
Durable biologics cash machine fairly priced on its base business; obesity is the swing factor.
The story
Amgen is a scaled biologics franchise. Steady volume growth in Repatha, Evenity, Tezspire and the Horizon rare-disease portfolio offsets biosimilar erosion of legacy drugs such as Prolia/Xgeva and Enbrel. MariTide gives it an obesity option, but that remains unproven, and the market price already gives it meaningful credit. The company is in mature mid-life: cash generation is strong, leverage from the Horizon acquisition is high, and its moat comes from biologics manufacturing scale and specialty commercial reach rather than any single patent.
TTM revenue grew about 6% and the operating margin reached 35.2%, so growth and margin move up modestly to match what was actually reported. I raised sales-to-capital from 0.7 to 0.9 (a material move). The reported 0.61 is depressed by Horizon goodwill. Incremental growth is funded by R&D and modest capex, not acquisitions. My prior 199 value implied a >100% gap with a widely covered stock, which signaled over-penalized reinvestment.
Value drivers
| Revenue growth (Y1) | 6.0% |
| Terminal growth | 2.5% |
| Forecast horizon | 8y |
| Target operating margin | 35.0% |
| Years to target margin | 3 |
| Sales-to-capital | 0.90 |
| Beta | 0.85 |
| Failure probability | 1.0% |
| Cost of capital (WACC) | 8.2% |
| Terminal WACC | 8.8% |
Valuation bridge
| PV of explicit FCFF | 68.89B |
| PV of terminal value | 117.00B |
| Equity value | 139.01B |
| ÷ shares → per share | $256.99 |
Projected free cash flow to the firm
| Yr | Revenue | Growth | Margin | NOPAT | Reinvest | FCFF | PV |
|---|---|---|---|---|---|---|---|
| 1 | 41.24B | 6.0% | 35.1% | 12.44B | 2.59B | 9.85B | 9.10B |
| 2 | 43.51B | 5.5% | 35.1% | 13.10B | 2.52B | 10.58B | 9.03B |
| 3 | 45.68B | 5.0% | 35.0% | 13.73B | 2.42B | 11.32B | 8.92B |
| 4 | 47.74B | 4.5% | 35.0% | 14.35B | 2.28B | 12.07B | 8.79B |
| 5 | 49.65B | 4.0% | 35.0% | 14.93B | 2.12B | 12.81B | 8.62B |
| 6 | 51.38B | 3.5% | 35.0% | 15.45B | 1.93B | 13.52B | 8.40B |
| 7 | 52.92B | 3.0% | 35.0% | 15.91B | 1.71B | 14.20B | 8.15B |
| 8 | 54.25B | 2.5% | 35.0% | 16.31B | 1.47B | 14.84B | 7.87B |
Key risks
- MariTide efficacy, tolerability or dosing disappoints against entrenched GLP-1 incumbents
- Biosimilar erosion of Prolia/Xgeva and Enbrel runs faster than new-product growth can offset
- IRA Medicare price negotiation and MFN-style pricing pressure compress US margins
Catalysts
- MariTide Phase 3 readouts and the design of its maintenance-dosing strategy
- Continued deleveraging of Horizon debt, lifting equity value per share